Study selection
Randomised controlled trials (RCTs) that compared antihypertensive treatment versus control for the prevention of cardiovascular events (fatal or nonfatal stroke, fatal or nonfatal myocardial infarction, congestive heart failure and mortality) in adults (aged >18 years) with blood pressure less than 140mmHg systolic or less than 90mmHg diastolic were eligible for inclusion. Eligible studies were required to include patients with pre-existing cardiovascular disease or cardiovascular disease equivalents (such as diabetes) and report either measures of variance or sufficient data for these to be calculated.
The included studies were of patients with a mean age range 54.8 to 68 years. The proportion of men was 76%. Clinical history of patients at baseline varied between trials. Blood pressure was measured using various assessment tools. Definitions of participants without hypertension varied among trials. Antihypertensive drugs included different types and doses of beta-blocker, angiotensin receptor blocker (ARB), calcium channel blocker, angiotensin-converting enzyme inhibitor (ACEI) and diuretics. Mean trial duration ranged between 1.5 and 63 months.
Three reviewers independently screened studies for inclusion. Discrepancies were resolved through consensus with two other reviewers.
Assessment of study quality
Two reviewers independently assessed study quality according to criteria of randomisation, allocation concealment, similarity of groups at baseline, eligibility criteria, blinding, point estimates and intention-to-treat analysis. Trials received a score out of nine. Discrepancies were resolved through discussion and consensus.
Data extraction
Three reviewers independently extracted or calculated relative risks (RRs) or hazard ratios, and 95% confidence intervals (CIs). Absolute risk reductions were calculated. Where necessary, primary authors were contacted for additional information. Discrepancies were resolved through discussion with two other reviewers.
Methods of synthesis
Relative risks and 95% CIs were combined using fixed-effect or random-effects models, weighted by the inverse of the variance. Absolute risk reductions and 95% CIs were combined using a random-effects model. The Q test and I 2 statistic were used to assess statistical heterogeneity.
Subgroup analyses were conducted to assess the influence of the presence or absence of comorbidities at baseline and type of antihypertensive treatment. Sensitivity analyses were performed by removal of one trial at a time and by restricting the analyses according to antihypertensive drug at baseline, definition of individuals without hypertension, trial size, follow-up duration and year of publication.
Publication bias was assessed using funnel plots and Begg and Eggers tests.
Results of the review
Twenty-five RCTs (n=64,162) were included in the review. Quality scores ranged between 7 and 9 (high quality).
Antihypertensive treatment statistically significantly reduced the risk of stroke (RR 0.77, 95% CI 0.61 to 0.98; seven RCTs, I 2 =61.9%), myocardial infarction ( Sensitivity analysis that removed one trial at a time resulted in non-significant findings for stroke, myocardial infarction and cardiovascular-related mortality. Other sensitivity analyses were reported in the review. Subgroup analysis showed non-significant findings using antihypertensive treatment for prevention of cardiovascular disease and all-cause mortality in patients with diabetes. Trial quality did not influence the findings on cardiovascular disease outcome or allcause mortality.
There was no evidence of publication bias using Begg test. There was evidence of bias for stroke using Eggers test, but the trim and fill adjustment method showed no change on the overall effect estimate.
